2025
The Central Vein Sign as a Radiologic Tool to Predict the Diagnosis of Radiation Necrosis in Intracranial Metastatic Cancer Patients
Antonios J, Adenu-Mensah N, Theriault B, Millares-Chavez M, Huttner A, Aboian M, Chiang V. The Central Vein Sign as a Radiologic Tool to Predict the Diagnosis of Radiation Necrosis in Intracranial Metastatic Cancer Patients. Clinical And Translational Neuroscience 2025, 9: 10. DOI: 10.3390/ctn9010010.Peer-Reviewed Original ResearchCentral vein signRadiation necrosisTumor progressionDiagnosis of radiation necrosisDifferentiate RNCerebral radiation necrosisIntracranial metastatic diseaseCancer therapy responseMetastatic cancer patientsNon-invasive markerMetastatic diseaseSurgical biopsyTherapy responsePredictive markerPatient cohortPrimary treatmentRadiological toolsCancer patientsRadiological imagingTreatment decisionsPerivascular spacesPatientsTreatmentNecrosisMarkers
2024
Topiramate treatment of pediatric metabolic dysfunction–associated steatotic liver disease: A descriptive cohort study
Kohut T, Tou A, Carr E, Xanthakos S, Arce‐Clachar A, Fawaz R, Valentino P, Panganiban J, Mouzaki M. Topiramate treatment of pediatric metabolic dysfunction–associated steatotic liver disease: A descriptive cohort study. Journal Of Parenteral And Enteral Nutrition 2024, 49: 308-313. PMID: 39720872, DOI: 10.1002/jpen.2722.Peer-Reviewed Original ResearchBody mass indexBody mass index z-scoreBaseline to 3Alanine aminotransferaseGlycated hemoglobinLifestyle modificationZ-scoreAlanine aminotransferase normalizationPatients aged <Weight loss medicationsAlanine aminotransferase levelsMild side effectsSerum alanine aminotransferaseObesity pharmacotherapyTopiramate treatmentPrimary treatmentLaboratory valuesOff-labelPediatric obesityMass indexTopiramateCohort studySingle agentPrimary outcomeLipid profilePrimary Treatment of Eyelid Conjunctival Melanoma with Immunotherapy: A Case Report
Weiss M, Perzia B, Sinard J, Tran T, Maeng M. Primary Treatment of Eyelid Conjunctival Melanoma with Immunotherapy: A Case Report. Ophthalmic Plastic And Reconstructive Surgery 2024, 41: e12-e15. PMID: 39240220, DOI: 10.1097/iop.0000000000002776.Peer-Reviewed Original ResearchConjunctival melanomaImmune checkpoint inhibitor regimenCombination of ipilimumabFirst-line combinationImmune checkpoint inhibitorsMonths of treatmentSystemic adverse effectsCutaneous melanoma treatmentHigher recurrence rateCheckpoint inhibitorsMucosal melanomaAdjuvant therapyDisease resolutionRecurrence rateLocal surgeryMelanoma treatmentFrequent metastasisCase reportPrimary treatmentMelanomaClinical approachIpilimumabNivolumabConjunctivalAdverse effectsErdheim–Chester Disease With Eyelid and Orbital Involvement: A Review of Treatment Modalities at One Institution From 2014 to 2022
Sharma M, Stevens S, Maeng M, Nagornaya N, Bhatia R, Wester S. Erdheim–Chester Disease With Eyelid and Orbital Involvement: A Review of Treatment Modalities at One Institution From 2014 to 2022. Ophthalmic Plastic And Reconstructive Surgery 2024, 40: 497-503. PMID: 38427815, PMCID: PMC11377047, DOI: 10.1097/iop.0000000000002619.Peer-Reviewed Original ResearchErdheim-Chester diseaseBascom Palmer Eye InstituteEye InstituteOrbital involvementTreatment of Erdheim-Chester diseaseErdheim-Chester disease patientsCase of Erdheim-Chester diseaseIntolerable side effectsRetrospective chart reviewFavorable treatment optionRelevant laboratory resultsReview of treatmentOphthalmic examinationDry eyeOphthalmic symptomsReducing proptosisBRAF inhibitorsECD patientsPathology reportsOphthalmic institutionsOrbital diseaseChart reviewTreatment modalitiesErdheim-ChesterPrimary treatment
2023
Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Benson A, Venook A, Al-Hawary M, Azad N, Chen Y, Ciombor K, Cohen S, Cooper H, Deming D, Garrido-Laguna I, Grem J, Hecht J, Hoffe S, Hubbard J, Hunt S, Hussan H, Jeck W, Johung K, Joseph N, Kirilcuk N, Krishnamurthi S, Maratt J, Messersmith W, Meyerhardt J, Miller E, Mulcahy M, Nurkin S, Overman M, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber J, Sofocleous C, Stotsky-Himelfarb E, Tavakkoli A, Willett C, Williams G, Algieri F, Gurski L, Stehman K. Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 653-677. PMID: 37308125, DOI: 10.6004/jnccn.2023.0030.Peer-Reviewed Original ResearchConceptsNCCN Clinical Practice GuidelinesAnal carcinomaClinical practice guidelinesPrimary treatmentPractice guidelinesSquamous cell anal carcinomaCommon histologic formExtrapelvic metastatic diseaseMetastatic anal carcinomaSystemic therapy recommendationsAnal canal cancerCurative-intent treatmentAJCC staging systemNCCN guidelinesPerianal cancerMetastatic diseasePersistent diseaseSystemic therapySurgical treatmentMedical oncologyStaging systemOptimal treatmentClinical evaluationHistologic formsTherapy recommendations
2022
Impact of Drug Exposure on Resistance Selection Following Artemether‐Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda
Kay K, Goodwin J, Ehrlich H, Ou J, Freeman T, Wang K, Li F, Wade M, French J, Huang L, Aweeka F, Mwebaza N, Kajubi R, Riggs M, Ruiz‐Garcia A, Parikh S. Impact of Drug Exposure on Resistance Selection Following Artemether‐Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda. Clinical Pharmacology & Therapeutics 2022, 113: 660-669. PMID: 36260349, PMCID: PMC9981240, DOI: 10.1002/cpt.2768.Peer-Reviewed Original ResearchConceptsLopinavir-ritonavirLumefantrine concentrationsSensitive parasitesRecurrence riskPopulation PK/PD modelArtemether-lumefantrine treatmentTrimethoprim-sulfamethoxazole prophylaxisPK/PD modelPopulation PK modelFirst-order absorptionHigh transmission regionsAntiretroviral regimensLumefantrine exposureLumefantrine susceptibilityPfcrt K76Pfmdr1 N86Suboptimal dosingArtemether-lumefantrineTwo-compartment modelHIV statusRecurrent infectionsCombination therapyDrug exposurePrimary treatmentArtemisinin resistancePatient-level and external factors in the use of drug-coated balloons and drug-eluting stents in femoropopliteal endovascular interventions
Castro-Dominguez Y, Smolderen KG, Pichert M, Alabi O, Romain G, Huang J, Lee M, Ahmed Z, Peri-Okonny PA, Arham A, Brice A, Chaar CO, Stacy MR, Mena-Hurtado C. Patient-level and external factors in the use of drug-coated balloons and drug-eluting stents in femoropopliteal endovascular interventions. Journal Of Vascular Surgery 2022, 76: 1675-1680. PMID: 35868423, DOI: 10.1016/j.jvs.2022.06.093.Peer-Reviewed Original ResearchConceptsDrug-coated balloonsDrug-eluting stentsBare metal stentsDES useFemoropopliteal endovascular interventionEndovascular interventionMedian odds ratioFemoropopliteal diseaseLesion characteristicsPrimary treatmentChronic kidney disease stage 4Adjusted median odds ratioVascular Quality Initiative registryAppropriate use guidelinesPrior anticoagulant usePatient-level factorsPoor functional statusTrans-Atlantic InterPlain balloon angioplastyPatient-level characteristicsFavorable patency ratesHierarchical logistic regression modelsLogistic regression modelsMeta-analysis publicationsRutherford classificationNon-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, DeCamp M, Dilling TJ, Dowell J, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Pacheco JM, Patel SP, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2022, 20: 497-530. PMID: 35545176, DOI: 10.6004/jnccn.2022.0025.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNCCN Clinical Practice GuidelinesCell lung cancerClinical practice guidelinesLung cancerPractice guidelinesMetastatic non-small cell lung cancerMetastatic lung cancerNCCN guidelinesPrimary treatmentTargeted therapyActionable mutationsPatientsCancerSubsequent treatmentTherapyOncologyTreatmentGuidelinesImmunotherapyRelapseDiagnosis
2021
Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series
Kowalczyk K, Madi R, Eden C, Sooriakumaran P, Fransis K, Raskin Y, Joniau S, Johnson S, Jacobsohn K, Galfano A, Bocciardi A, Hwang J, Kim I, Hu J. Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series. Journal Of Urology 2021, 206: 1184-1191. PMID: 34181471, DOI: 10.1097/ju.0000000000001939.Peer-Reviewed Original ResearchConceptsRobotic-assisted radical prostatectomyAssisted radical prostatectomyConsole timeRadical prostatectomyPrimary treatmentStereotactic body radiation therapyFeasible salvage optionNonsurgical primary treatmentPostoperative pad useUrinary function outcomesRisk of incontinenceKaplan-Meier curvesBody radiation therapyProportional hazards modelLonger console timeT-testStudent's t-testPostoperative complicationsMedian followupOncologic outcomesPerioperative dataBlood lossComplication rateSalvage optionFunction outcomesMycophenolate as Primary Treatment for Immune Checkpoint Inhibitor Induced Acute Kidney Injury in a Patient with Concurrent Immunotherapy-Associated Diabetes: A Case Report.
Jessel S, Austin M, Kluger HM. Mycophenolate as Primary Treatment for Immune Checkpoint Inhibitor Induced Acute Kidney Injury in a Patient with Concurrent Immunotherapy-Associated Diabetes: A Case Report. Clinical Oncology Case Reports 2021, 4 PMID: 33763663, PMCID: PMC7985664.Peer-Reviewed Original ResearchAcute kidney injuryImmune checkpoint inhibitorsKidney injuryCheckpoint inhibitorsT cellsImmune-related adverse eventsCycles of nivolumabEffective frontline therapyAggressive fluid resuscitationSteroid-sparing agentRegulatory T cellsInitiation of insulinT cell responsesCytotoxic T cellsMycophenolate mofetilAdverse eventsFrontline therapyRenal functionComplete responseFluid resuscitationKidney functionCase reportMetastatic melanomaPrimary treatmentTumor types
2020
The Surgical Resection of Brainstem Glioma: Outcomes and Prognostic Factors
Faulkner H, Arnaout O, Hoshide R, Young IM, Yeung JT, Sughrue ME, Teo C. The Surgical Resection of Brainstem Glioma: Outcomes and Prognostic Factors. World Neurosurgery 2020, 146: e639-e650. PMID: 33152495, DOI: 10.1016/j.wneu.2020.10.147.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAstrocytomaAtaxiaBrain Stem NeoplasmsCerebrospinal Fluid LeakChildChild, PreschoolDiplopiaEpendymomaFemaleGlioblastomaGliomaHeadacheHumansHydrocephalusInfantInfant, NewbornKaplan-Meier EstimateKarnofsky Performance StatusMachine LearningMagnetic Resonance ImagingMaleMiddle AgedMultivariate AnalysisNauseaNeoplasm GradingNeoplasm, ResidualNeurosurgical ProceduresPostoperative ComplicationsPrognosisRetrospective StudiesSurvival RateTumor BurdenVomitingYoung AdultConceptsBrainstem gliomasSurgical resectionPrognostic factorsSurgical treatmentTransient neurologic deficitsRadical surgical resectionHigh-grade tumorsPostoperative radiographic evaluationMagnetic resonance imagingChart reviewNeurologic deficitsOverall survivalSurgical candidatesConfers survival advantageMedian ageSurgical indicationsPatient selectionSurvival outcomesRadiographic evaluationSelect subgroupRadiographic featuresPrimary treatmentPermanent deficitsSurvival advantageTreatment selectionRandomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. Clinical Cancer Research 2020, 26: 3928-3935. PMID: 32601075, PMCID: PMC8792803, DOI: 10.1158/1078-0432.ccr-20-0953.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinChemotherapy, AdjuvantCystadenocarcinoma, SerousCytoreduction Surgical ProceduresDrug Administration ScheduleEndometrial NeoplasmsEndometriumFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPaclitaxelProgression-Free SurvivalReceptor, ErbB-2Survival AnalysisTrastuzumabConceptsProgression-free survivalRandomized phase II trialPhase II trialOverall survivalHER2/neuStage IIICarboplatin-paclitaxelII trialRecurrent diseaseControl armSurvival analysisRecurrent uterine serous carcinomaCarboplatin/paclitaxelUterine serous carcinomaOverall survival analysisEvaluable patientsEligible patientsPrimary endpointSecondary endpointsEndometrial cancerAggressive variantSerous carcinomaPrimary treatmentSurvival medianPatients
2019
223: Outcomes after Solomon fetoscopic laser as the primary treatment for twin-twin-transfusion syndrome
Faden M, Chang R, Ong C, Miller J, Baschat A. 223: Outcomes after Solomon fetoscopic laser as the primary treatment for twin-twin-transfusion syndrome. American Journal Of Obstetrics And Gynecology 2019, 220: s161-s162. DOI: 10.1016/j.ajog.2018.11.244.Peer-Reviewed Original Research
2018
New England BK consortium: Regional survey of BK screening and management protocols in comparison to published consensus guidelines
Gabardi S, Pavlakis M, Tan C, Francis J, Cardarelli F, Asch W, Bodziak K, Chobanian M, Gilligan H, Gohh R, Kung S, Inker L, Martin S, Rodig N, Rossi A, Chandraker A. New England BK consortium: Regional survey of BK screening and management protocols in comparison to published consensus guidelines. Transplant Infectious Disease 2018, 20: e12985. PMID: 30175491, DOI: 10.1111/tid.12985.Peer-Reviewed Original ResearchConceptsRenal transplant recipientsConsensus guidelinesBKPyV-associated nephropathyCNI dose reductionPlasma viral loadUse of leflunomideCopies/mLHalf of centersMajority of centersManagement protocolCause biopsiesImmunosuppression reductionIntravenous immunoglobulinTransplant recipientsRenal biopsyViral loadBK polyomavirusPrimary treatmentDose reductionBiopsyUniform screeningNephropathyBKPyVShort durationScreeningSurvival Rates after Thermal Ablation versus Stereotactic Radiation Therapy for Stage 1 Non-Small Cell Lung Cancer: A National Cancer Database Study.
Uhlig J, Ludwig JM, Goldberg SB, Chiang A, Blasberg JD, Kim HS. Survival Rates after Thermal Ablation versus Stereotactic Radiation Therapy for Stage 1 Non-Small Cell Lung Cancer: A National Cancer Database Study. Radiology 2018, 289: 862-870. PMID: 30226453, DOI: 10.1148/radiol.2018180979.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStage 1 non-small cell lung cancerStereotactic radiation therapyCell lung cancerOverall survivalLung cancerThermal ablationRadiation therapySurvival ratePropensity score-matched cohortUnplanned hospital readmission ratesNational Cancer DatabaseUnplanned hospital readmissionOverall survival rateHospital readmission ratesSmaller tumor sizeMore comorbiditiesReadmission ratesHospital readmissionRetrospective studyTumor sizePotential confoundersCancer DatabasePrimary treatmentPatientsAttentional bias in opioid users: A systematic review and meta-analysis
MacLean RR, Sofuoglu M, Brede E, Robinson C, Waters AJ. Attentional bias in opioid users: A systematic review and meta-analysis. Drug And Alcohol Dependence 2018, 191: 270-278. PMID: 30157467, DOI: 10.1016/j.drugalcdep.2018.07.012.Peer-Reviewed Original ResearchConceptsAttentional biasNeutral stimuliBehavioral treatmentRobust attentional biasAdjunctive behavioral treatmentsOpioid use disorderAttention biasOpioid cuesSalient stimuliEligible peer-reviewed studiesStimuliUse disordersOpioid usersCurrent studySystematic reviewPeer-reviewed studiesNational public health emergencyBiasComprehensive literature searchTreatment outcomesPublic health emergencyOpioid useActive responseCuesPrimary treatmentPhosphaturic mesenchymal tumors: what an endocrinologist should know
Boland J, Tebben P, Folpe A. Phosphaturic mesenchymal tumors: what an endocrinologist should know. Journal Of Endocrinological Investigation 2018, 41: 1173-1184. PMID: 29446010, DOI: 10.1007/s40618-018-0849-5.Peer-Reviewed Original ResearchConceptsTumor-induced osteomalaciaPhosphaturic mesenchymal tumorMesenchymal tumorsCase of tumor-induced osteomalaciaRare cause of osteomalaciaPhosphaturic hormone fibroblast growth factor 23Recurrent genetic eventsHormone fibroblast growth factor 23Renal phosphate wastingFibroblast growth factor 23Autocrine/paracrine signaling loopTubular phosphate reabsorptionProgressive muscle weaknessProximal tubular phosphate reabsorptionConstellation of symptomsMolecular genetic aspectsBone painCalcitriol therapyCurative surgeryOncogenic osteomalaciaOffending tumorRare causeSurgical removalClinical featuresPrimary treatmentIn Vivo Antiplasmodial Activity of Two Sahelian Plant Extracts on Plasmodium berghei ANKA Infected NMRI Mice
Bonkian L, Yerbanga R, Koama B, Soma A, Cisse M, Valea I, Tinto H, Ouedraogo J, Guigemde T, Traore/Coulibaly M. In Vivo Antiplasmodial Activity of Two Sahelian Plant Extracts on Plasmodium berghei ANKA Infected NMRI Mice. Evidence-based Complementary And Alternative Medicine 2018, 2018: 6859632. PMID: 29977316, PMCID: PMC5994278, DOI: 10.1155/2018/6859632.Peer-Reviewed Original ResearchArtemisinin-based combination therapyWorld Health OrganizationNMRI miceBody weightUncomplicated malaria treatmentAntiplasmodial activityVivo antiplasmodial activityPercentage of reductionFour-day treatmentControl of malariaExtract/Thin blood smearsCombination therapyMalaria treatmentPrimary treatmentControl groupDay fiveBlood smearsCandidate drugsHerbal medicineHealth OrganizationMalariaLeaf decoctionTreatmentParasitaemia
2017
Retinoblastoma: A Sixteen-Year Review of the Presentation, Treatment, and Outcome from a Tertiary Care Institute in Northern India
Singh U, Katoch D, Kaur S, Dogra M, Bansal D, Kapoor R. Retinoblastoma: A Sixteen-Year Review of the Presentation, Treatment, and Outcome from a Tertiary Care Institute in Northern India. Ocular Oncology And Pathology 2017, 4: 23-32. PMID: 29344495, PMCID: PMC5757564, DOI: 10.1159/000477408.Peer-Reviewed Original ResearchRetinoblastoma patientsHistopathological high-risk featuresHistopathological risk factorsHigh-risk featuresTertiary care institutionRate of metastasisDefaulted therapyExtraocular extensionIntraocular diseasePrimary enucleationLocal recurrenceAdvanced diseaseRetrospective reviewPediatric patientsClinical characteristicsPrimary treatmentChemoreductionRisk featuresPatientsRisk factorsTherapy refusalStudy epidemiologyRetinoblastomaEnucleationMetastasis
2016
Commentary: Are alpha‐2 agonist really effective in children with tics with comorbid ADHD? A commentary on Whittington et al. (2016)
Bloch MH. Commentary: Are alpha‐2 agonist really effective in children with tics with comorbid ADHD? A commentary on Whittington et al. (2016). Journal Of Child Psychology And Psychiatry 2016, 57: 1005-1007. PMID: 27535650, DOI: 10.1111/jcpp.12592.Peer-Reviewed Original ResearchConceptsAlpha-2 agonistsComorbid ADHDComprehensive Behavioral InterventionAdrenergic receptor agonistAgonist medicationsAntipsychotic medicationReceptor agonistPrimary treatmentTic disordersSystematic reviewMedicationsBehavioral interventionsAgonistsEffects of ADHDEfficacyTreatmentADHDChildrenPossible explanationPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply